HRP20150360T1 - Poksvirusni onkolitiäśki vektori - Google Patents
Poksvirusni onkolitiäśki vektori Download PDFInfo
- Publication number
- HRP20150360T1 HRP20150360T1 HRP20150360TT HRP20150360T HRP20150360T1 HR P20150360 T1 HRP20150360 T1 HR P20150360T1 HR P20150360T T HRP20150360T T HR P20150360TT HR P20150360 T HRP20150360 T HR P20150360T HR P20150360 T1 HRP20150360 T1 HR P20150360T1
- Authority
- HR
- Croatia
- Prior art keywords
- poxvirus
- pharmaceutical preparation
- accordance
- treatment
- intended
- Prior art date
Links
- 230000000174 oncolytic effect Effects 0.000 title 1
- 239000013598 vector Substances 0.000 title 1
- 201000010099 disease Diseases 0.000 claims 22
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 22
- 230000000694 effects Effects 0.000 claims 15
- 239000000825 pharmaceutical preparation Substances 0.000 claims 12
- 210000002997 osteoclast Anatomy 0.000 claims 11
- 230000002062 proliferating effect Effects 0.000 claims 11
- 108090000623 proteins and genes Proteins 0.000 claims 10
- 108090000301 Membrane transport proteins Proteins 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 239000000126 substance Substances 0.000 claims 4
- 102000000311 Cytosine Deaminase Human genes 0.000 claims 3
- 108010080611 Cytosine Deaminase Proteins 0.000 claims 3
- 241000700618 Vaccinia virus Species 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 3
- 231100000433 cytotoxic Toxicity 0.000 claims 3
- 230000001472 cytotoxic effect Effects 0.000 claims 3
- XRECTZIEBJDKEO-UHFFFAOYSA-N flucytosine Chemical compound NC1=NC(=O)NC=C1F XRECTZIEBJDKEO-UHFFFAOYSA-N 0.000 claims 3
- 229960004413 flucytosine Drugs 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 3
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 claims 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- 101100502554 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) FCY1 gene Proteins 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 230000002950 deficient Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 229920001184 polypeptide Polymers 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 239000000651 prodrug Substances 0.000 claims 2
- 229940002612 prodrug Drugs 0.000 claims 2
- ZZKNRXZVGOYGJT-VKHMYHEASA-N (2s)-2-[(2-phosphonoacetyl)amino]butanedioic acid Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)CP(O)(O)=O ZZKNRXZVGOYGJT-VKHMYHEASA-N 0.000 claims 1
- 101100226898 Candida albicans (strain SC5314 / ATCC MYA-2876) FCA1 gene Proteins 0.000 claims 1
- 241000700628 Chordopoxvirinae Species 0.000 claims 1
- 108050000190 Cytosine permeases Proteins 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 101000807008 Homo sapiens Uracil phosphoribosyltransferase homolog Proteins 0.000 claims 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims 1
- 101100502558 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) FCY2 gene Proteins 0.000 claims 1
- 102100037717 Uracil phosphoribosyltransferase homolog Human genes 0.000 claims 1
- 230000006696 biosynthetic metabolic pathway Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 238000004113 cell culture Methods 0.000 claims 1
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 claims 1
- 229960000681 leflunomide Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229960000485 methotrexate Drugs 0.000 claims 1
- 108010087864 purine permease Proteins 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- UTNUDOFZCWSZMS-YFHOEESVSA-N teriflunomide Chemical compound C\C(O)=C(/C#N)C(=O)NC1=CC=C(C(F)(F)F)C=C1 UTNUDOFZCWSZMS-YFHOEESVSA-N 0.000 claims 1
- 108091000036 uracil phosphoribosyltransferase Proteins 0.000 claims 1
- 108700026220 vif Genes Proteins 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/863—Poxviral vectors, e.g. entomopoxvirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Mycology (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
Claims (28)
1. Poksvirus, naznačen time što sadrži defektni gen F2L, defektni gen J2R i nukleinsku kiselinu od interesa koja sadrži gen za samoubojstvo.
2. Poksvirus u skladu s patentnim zahtjevom 1, naznačen time što navedeni poksvirus pripada potporodici Chordopoksvirinae.
3. Poksvirus u skladu s patentnim zahtjevom 2, naznačen time što navedeni poksvirus pripada vrsti virusa vakcinije.
4. Poksvirus u skladu s patentnim zahtjevom 3, naznačen time što je navedeni poksvirus soj WR virusa vakcinije.
5. Poksvirus u skladu s patentnim zahtjevom 3, naznačen time što je navedeni poksvirus soj Copenhagen virusa vakcinije.
6. Poksvirus u skladu s bilo kojim od patentnih zahtjeva 1 do 5, naznačen time što navedeni gen za samoubojstvo kodira protein ima najmanje aktivnost citozinske deaminaze.
7. Poksvirus u skladu s patentnim zahtjevom 6, naznačen time što je navedeni gen za samoubojstvo FCY1, FCA1 ili CodA ili njegov analog.
8. Poksvirus u skladu s patentnim zahtjevom 6, naznačen time što navedeni protein koji u najmanju ruku ima aktivnost citozinske deaminaze je FCU1-8 polipeptid prikazan u identifikatoru slijeda SEQ ID NO:2 i njegovim analozima.
9. Poksvirus u skladu s bilo kojim od patentnih zahtjeva 1 do 5, naznačen time što navedeni gen za samoubojstvo kodira protein koji ima najmanje jednu aktivnost citozinske deaminaze i jednu aktivnost uracil fosforiboziltransferaze.
10. Poksvirus u skladu s patentnim zahtjevom 9, naznačen time što navedeni gen za samoubojstvo kodira polipeptid koji sadrži aminokiselinski slijed kao što je uglavnom prikazan u identifikatoru slijeda SEQ ID NO:3 (codA::upp), SEQ ID NO:1 (FCU1) ili aminokiselinski slijed FCY1::FUR1.
11. Poksvirus u skladu s bilo kojim od patentnih zahtjeva 1 do 10, naznačen time što navedeni poksvirus dodatno sadrži nukleinskokiselinski slijed koji sadrži gen koji kodira permeazu.
12. Poksvirus u skladu s patentnim zahtjevom 11, naznačen time što je permeaza purinska ili citozinska permeaza iz kvasca S. cerevisiae.
13. Poksvirus u skladu s patentnim zahtjevom 12, naznačen time što se permeaza bira iz skupine koju čine FCY2 i Fur4 i njihovi analozi.
14. Poksvirus u skladu s bilo kojim od patentnih zahtjeva 1 do 10, naznačen time što navedeni poksvirus dodatno sadrži elemente nužne za eksprimiranje nukleinske kiseline od interesa.
15. Poksvirus u skladu s bilo kojim od patentnih zahtjeva 11 do 13, naznačen time što navedeni poksvirus dodatno sadrži elemente nužne za eksprimiranje nukleinskokiselinskog slijeda koji sadrži gen koji kodira permeazu.
16. Poksvirus u skladu s bilo kojim od patentnih zahtjeva 1 do 15, naznačen time što je namijenjen upotrebi u liječenju proliferativne bolesti ili bolesti povezane s pojačanom aktivnošću osteoklasta.
17. Postupak priprave poksvirusa u skladu s bilo kojim od patentnih zahtjeva 1 do 15, naznačen time što u navedenom postupku:
(i) u stanicu se unosi poksvirus u skladu s bilo kojim od patentnih zahtjeva 1 do 15;
(ii) navedenu stanicu se uzgaja u uvjetima prikladnim za omogućavanje dobivanja navedenog poksvirusa, te;
(iii) navedeni poksvirus se prikuplja iz kulture stanica.
18. Farmaceutski pripravak, naznačen time što sadrži poksvirus u skladu s bilo kojim od patentnih zahtjeva 1 do 15, kao i farmaceutski prihvatljivu pomoćnu tvar.
19. Farmaceutski pripravak u skladu s patentnim zahtjevom 18, naznačen time što sadrži jednu ili više tvari koje pojačavaju citotoksični učinak 5-fluorcitozina.
20. Farmaceutski pripravak u skladu s patentnim zahtjevom 19, naznačen time što su navedene tvari koje pojačavaju citotoksični učinak 5-fluorcitozina lijekovi koji inhibiraju enzime u putu biosinteze pirimidina de novo, koje se po mogućnosti bira iz skupine koju čine PALA, leflunomid i A771726.
21. Farmaceutski pripravak u skladu s patentnim zahtjevom 19, naznačen time što je navedena tvar koja pojačava citotoksični učinak 5-fluorcitozina metotreksat.
22. Farmaceutski pripravak u skladu s bilo kojim od patentnih zahtjeva 18 do 21, naznačen time što je namijenjen upotrebi u liječenju proliferativne bolesti ili bolesti povezane s pojačanom aktivnošću osteoklasta.
23. Poksvirus, namijenjen upotrebi u liječenju proliferativne bolesti ili bolesti povezane s pojačanom aktivnošću osteoklasta u skladu s patentnim zahtjevom, 16 ili farmaceutski pripravak, namijenjen upotrebi u liječenju proliferativne bolesti ili bolesti povezane s pojačanom aktivnošću osteoklasta u skladu s patentnim zahtjevom 22, naznačeni time što je proliferativna bolest rak ili restenoza.
24. Poksvirus, namijenjen upotrebi u liječenju proliferativne bolesti ili bolesti povezane s pojačanom aktivnošću osteoklasta u skladu s patentnim zahtjevom, 16 ili farmaceutski pripravak, namijenjen upotrebi u liječenju proliferativne bolesti ili bolesti povezane s pojačanom aktivnošću osteoklasta u skladu s patentnim zahtjevom 22, naznačeni time je bolest povezana s pojačanom aktivnošću osteoklasta reumatoidni artritis ili osteoporoza.
25. Farmaceutski pripravak, namijenjen upotrebi u liječenju proliferativne bolesti ili bolesti povezane s pojačanom aktivnošću osteoklasta u skladu s bilo kojim od patentnih zahtjeva 22 do 24, naznačen time što se farmaceutski pripravak primijenjuje sistemno.
26. Farmaceutski pripravak, namijenjen upotrebi u liječenju proliferativne bolesti ili bolesti povezane s pojačanom aktivnošću osteoklasta u skladu s bilo kojim od patentnih zahtjeva 22 do 25, naznačen time što se na navedenom organizmu ili stanici domaćina dodatno primjenjuje predlijek.
27. Farmaceutski pripravak, namijenjen upotrebi u liječenju proliferativne bolesti ili bolesti povezane s pojačanom aktivnošću osteoklasta u skladu s patentnim zahtjevom 26, naznačen time što se navedeni predlijek primjenjuje najmanje 3 dana, po mogućnosti najmanje 4 dana, a poželjnije najmanje 5 dana nakon primjene navedenog poksvirusa ili pripravka.
28. Farmaceutski pripravak, namijenjen upotrebi u liječenju proliferativne bolesti ili bolesti povezane s pojačanom aktivnošću osteoklasta u skladu s patentnim zahtjevom 27, naznačen time što se navedeni predlijek primjenjuje 7 dana nakon primjene navedenog poksvirusa ili pripravka.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07301556 | 2007-11-19 | ||
| PCT/EP2008/009721 WO2009065547A2 (en) | 2007-11-19 | 2008-11-17 | Poxviral oncolytic vectors |
| EP08851361.9A EP2212423B1 (en) | 2007-11-19 | 2008-11-17 | Poxviral oncolytic vectors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20150360T1 true HRP20150360T1 (hr) | 2015-05-08 |
Family
ID=40548531
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20150360TT HRP20150360T1 (hr) | 2007-11-19 | 2015-03-30 | Poksvirusni onkolitiäśki vektori |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US9180150B2 (hr) |
| EP (1) | EP2212423B1 (hr) |
| JP (1) | JP5710262B2 (hr) |
| KR (1) | KR101542275B1 (hr) |
| CN (1) | CN101868546B (hr) |
| AU (1) | AU2008328258B2 (hr) |
| BR (1) | BRPI0820578A2 (hr) |
| CA (1) | CA2705873C (hr) |
| CO (1) | CO6210761A2 (hr) |
| CR (1) | CR11520A (hr) |
| DK (1) | DK2212423T3 (hr) |
| EC (1) | ECSP10010287A (hr) |
| ES (1) | ES2535633T3 (hr) |
| HK (1) | HK1141314A1 (hr) |
| HR (1) | HRP20150360T1 (hr) |
| IL (1) | IL204539A (hr) |
| MX (1) | MX2010005273A (hr) |
| NZ (1) | NZ584201A (hr) |
| PL (1) | PL2212423T3 (hr) |
| RU (2) | RU2508401C2 (hr) |
| WO (1) | WO2009065547A2 (hr) |
| ZA (1) | ZA201004286B (hr) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2010205717A1 (en) | 2009-01-13 | 2010-07-22 | Transgene Sa | Use of a Saccharomyces cerevisiae mitochondrial nucleic acids fraction for immune stimulation |
| CA2760465A1 (en) | 2009-05-12 | 2010-11-18 | Transgene Sa | Method for orthopoxvirus production and purification |
| HUE028240T2 (en) | 2009-07-10 | 2016-12-28 | Transgene Sa | Biomarker Patient Selection and Related Procedures |
| WO2013004658A1 (en) | 2011-07-01 | 2013-01-10 | Transgene Sa | Formulations of 5-fluorocytosine and uses thereof. |
| TWI690322B (zh) | 2012-10-02 | 2020-04-11 | 法商傳斯堅公司 | 含病毒的調配物及其使用 |
| JP6843736B2 (ja) * | 2014-07-16 | 2021-03-17 | トランジェーヌＴｒａｎｓｇｅｎｅ | 腫瘍溶解性ウイルスと免疫チェックポイントモジュレーターとの組合せ |
| PL3169341T3 (pl) | 2014-07-16 | 2019-12-31 | Transgene Sa | Wirus onkolityczny do ekspresji modulatorów punktu kontroli immunologicznej |
| DK3226894T3 (da) | 2014-12-01 | 2019-10-21 | Transgene Sa | Stabile flydende vacciniavirus-formuleringer |
| WO2016131945A1 (en) | 2015-02-20 | 2016-08-25 | Transgene Sa | Combination product with autophagy modulator |
| CA2977660A1 (en) | 2015-02-25 | 2016-09-15 | Memorial Sloan-Kettering Cancer Center | Use of inactivated nonreplicating modified vaccinia virus ankara (mva) as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors |
| CA2982896A1 (en) | 2015-04-17 | 2016-10-20 | Memorial Sloan Kettering Cancer Center | Use of modified vaccinia ankara virus (mva) or mva with a deletion of virulence factor e8 as immunotherapeutic agent against solid tumors |
| MX2018010204A (es) | 2016-02-25 | 2019-05-06 | Memorial Sloan Kettering Cancer Center | Virus de la vaccinia atenuada competentes para replicacion con la supresion de timidina quinasa con y sin la expresion del flt3l o gm-csf humanos para inmunoterapia del cancer. |
| MX2018010231A (es) | 2016-02-25 | 2019-06-06 | Memorial Sloan Kettering Cancer Center | Mva recombinante o mvadele3l que expresa el flt3l humano y uso de los mismos como agentes inmunoterapéuticos contra tumores sólidos. |
| CA3023022A1 (en) | 2016-05-04 | 2017-11-09 | Transgene Sa | Combination therapy with cpg tlr9 ligand |
| KR20230113832A (ko) * | 2016-08-09 | 2023-08-01 | 시티 오브 호프 | 키메라 폭스바이러스 조성물 및 이의 용도 |
| US20190328869A1 (en) | 2016-10-10 | 2019-10-31 | Transgene Sa | Immunotherapeutic product and mdsc modulator combination therapy |
| KR20190097240A (ko) | 2016-12-28 | 2019-08-20 | 트랜스진 에스.에이. | 종양용해성 바이러스 및 치료 분자 |
| CN111107872A (zh) | 2017-05-12 | 2020-05-05 | 纪念斯隆-凯特林癌症中心 | 有用于癌症免疫疗法的牛痘病毒突变体 |
| EP3641803A2 (en) | 2017-06-21 | 2020-04-29 | Transgene | Personalized vaccine |
| WO2019020543A1 (en) | 2017-07-28 | 2019-01-31 | Transgene Sa | ONCOLYTIC VIRUSES EXPRESSING AGENTS TARGETING METABOLIC IMMUNE MODULATORS |
| JP7391831B2 (ja) * | 2017-08-11 | 2023-12-05 | シティ・オブ・ホープ | Ｃａｒ ｔ細胞標的を発現する腫瘍溶解性ウイルス、及びその使用 |
| AU2019212840A1 (en) | 2018-01-26 | 2020-07-16 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Expression of metabolic modulators in tumor microenvironment to improve tumor therapy |
| AU2019412516A1 (en) | 2018-12-28 | 2021-07-15 | Transgene | M2-defective poxvirus |
| WO2022148736A1 (en) | 2021-01-05 | 2022-07-14 | Transgene | Vectorization of muc1 t cell engager |
| WO2023213764A1 (en) | 2022-05-02 | 2023-11-09 | Transgene | Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf |
| WO2023213763A1 (en) | 2022-05-02 | 2023-11-09 | Transgene | Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab |
| WO2024003353A1 (en) | 2022-07-01 | 2024-01-04 | Transgene | Fusion protein comprising a surfactant-protein-d and a member of the tnfsf |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5364773A (en) | 1991-03-07 | 1994-11-15 | Virogenetics Corporation | Genetically engineered vaccine strain |
| US5225336A (en) * | 1989-03-08 | 1993-07-06 | Health Research Incorporated | Recombinant poxvirus host range selection system |
| EP0575491B1 (en) * | 1991-03-07 | 2003-08-13 | Virogenetics Corporation | Genetically engineered vaccine strain |
| EP1367128A1 (en) * | 1991-03-07 | 2003-12-03 | Connaught Technology Corporation | Genetically engineered vaccine strain |
| US20030044384A1 (en) * | 1997-10-09 | 2003-03-06 | Pro-Virus, Inc. | Treatment of neoplasms with viruses |
| CA2375189C (en) * | 1999-05-28 | 2010-02-09 | The Government Of The United States Of America | A combined growth factor-deleted and thymidine kinase-deleted vaccinia virus vector |
| US6897057B1 (en) * | 1999-08-31 | 2005-05-24 | The General Hospital Corporation | Cell-specific and/or tumor-specific promoter retargeting of herpes γ 34.5 gene expression |
| DE602004018927D1 (de) * | 2003-06-18 | 2009-02-26 | Genelux Corp | Modifizierte rekombinante vacciniaviren, verwendungen davon |
| NZ584199A (en) * | 2007-11-19 | 2012-07-27 | Transgene Sa | Poxviral oncolytic vectors comprising a defective 14l and/or f4l gene |
-
2008
- 2008-11-17 MX MX2010005273A patent/MX2010005273A/es active IP Right Grant
- 2008-11-17 RU RU2010124613/10A patent/RU2508401C2/ru not_active IP Right Cessation
- 2008-11-17 JP JP2010533511A patent/JP5710262B2/ja not_active Expired - Fee Related
- 2008-11-17 NZ NZ584201A patent/NZ584201A/en not_active IP Right Cessation
- 2008-11-17 PL PL08851361T patent/PL2212423T3/pl unknown
- 2008-11-17 WO PCT/EP2008/009721 patent/WO2009065547A2/en active Application Filing
- 2008-11-17 US US12/743,412 patent/US9180150B2/en not_active Expired - Fee Related
- 2008-11-17 AU AU2008328258A patent/AU2008328258B2/en not_active Ceased
- 2008-11-17 KR KR1020107010821A patent/KR101542275B1/ko active IP Right Grant
- 2008-11-17 DK DK08851361T patent/DK2212423T3/en active
- 2008-11-17 CN CN2008801168337A patent/CN101868546B/zh not_active Expired - Fee Related
- 2008-11-17 EP EP08851361.9A patent/EP2212423B1/en not_active Not-in-force
- 2008-11-17 CA CA2705873A patent/CA2705873C/en not_active Expired - Fee Related
- 2008-11-17 RU RU2013129678/10A patent/RU2557312C2/ru not_active IP Right Cessation
- 2008-11-17 BR BRPI0820578-7A patent/BRPI0820578A2/pt not_active Application Discontinuation
- 2008-11-17 ES ES08851361.9T patent/ES2535633T3/es active Active
-
2010
- 2010-03-16 IL IL204539A patent/IL204539A/en active IP Right Grant
- 2010-06-17 ZA ZA2010/04286A patent/ZA201004286B/en unknown
- 2010-06-18 CO CO10073787A patent/CO6210761A2/es not_active Application Discontinuation
- 2010-06-18 EC EC2010010287A patent/ECSP10010287A/es unknown
- 2010-06-18 CR CR11520A patent/CR11520A/es not_active Application Discontinuation
- 2010-08-17 HK HK10107869.1A patent/HK1141314A1/xx not_active IP Right Cessation
-
2015
- 2015-03-30 HR HRP20150360TT patent/HRP20150360T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20150360T1 (hr) | Poksvirusni onkolitiäśki vektori | |
| CA2705869A1 (en) | Poxviral oncolytic vectors | |
| JP2011504105A5 (hr) | ||
| Wang et al. | Draft genome sequence of Streptomyces globisporus C-1027, which produces an antitumor antibiotic consisting of a nine-membered enediyne with a chromoprotein | |
| EP3129037B1 (en) | Poxviral oncolytic vectors | |
| Gong et al. | Mapping the active site of vaccinia virus RNA triphosphatase | |
| US9687515B2 (en) | Poxviral oncolytic vectors | |
| Douglass | Molecular and evolutionary analysis of a gene conserved in most Orthopoxviruses |